| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5196404 | SANDOZ | Inhibitors of thrombin |
Dec, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5196404 (Pediatric) | SANDOZ | Inhibitors of thrombin |
Jun, 2015
(8 years ago) | |
| US7598343 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
| US7582727 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
|
US7582727 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) | |
|
US7598343 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) | |
Angiomax is owned by Sandoz.
Angiomax contains Bivalirudin.
Angiomax has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Angiomax are:
- US5196404*PED
- US5196404
Angiomax was authorised for market use on 15 December, 2000.
Angiomax is available in injectable;intravenous dosage forms.
Angiomax can be used as inhibition of thrombin in a patient.
The generics of Angiomax are possible to be released after 27 January, 2029.
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: Inhibition of thrombin in a patient
Dosage: INJECTABLE;INTRAVENOUS
ANGIOMAX family patents
